3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Melanoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rare Tumour
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Thyroid Gland Carcinoma
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Lobular
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Doxorubicin
62
Ifosfamide
39
Gemcitabine
29
Radiotherapy
27
Filgrastim
27
Cyclophosphamide
26
Docetaxel
19
Vincristine
18
pembrolizumab
17
Etoposide
17
pazopanib
16
Cisplatin
16
Nivolumab
15
Trabectedin
14
apatinib
13
Magnetic Resonance Spectroscopy
13
Carboplatin
12
Irinotecan
11
Bevacizumab
11
Temozolomide
10
Sirolimus
10
camrelizumab
9
anlotinib
9
Surgical Procedures, Operative
9
Sorafenib
9
Paclitaxel
9
Ipilimumab
9
Injections
9
Dactinomycin
9
Topotecan
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA